Immune Checkpoint Inhibitors in Hepatocellular Carcinoma A New Era in Treatment of Advanced Disease
ABSTRACT Hepatocellular carcinoma (HCC) is the most prevalent primary hepatic cancer with high fatality and recurrence rates. The prognosis of advanced HCC is dismal, and treatment was limited for a decade to sorafenib with limited effectiveness and miserable overall survival. The advent of immune checkpoint inhibitors (ICPIs) provides a considerable step in the treatment of several advanced malignancies including HCC ... إقراء المزيد